Ars Pharmaceuticals [SPRY] vs Vertex [VRTX] Detailed Stock Comparison

Ars Pharmaceuticals Inc

NASDAQ
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Ars Pharmaceuticals Inc wins in 1 metrics, Vertex Pharmaceuticals Inc. wins in 18 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Ars Pharmaceuticals Inc Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) 168.25 28.40 Vertex Pharmaceuticals Inc.
Price-to-Book Ratio 6.81 5.92 Vertex Pharmaceuticals Inc.
Debt-to-Equity Ratio 147.49 10.91 Vertex Pharmaceuticals Inc.
PEG Ratio -10.35 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA -3.94 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) -203.25% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) -147.63% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) N/A 39.60% N/A
Return on Equity -92.33% 22.54% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) -33.04% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-171.21M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return -37.14% 1.24% Vertex Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 9.24 9.22 Vertex Pharmaceuticals Inc.
Enterprise Value $702.02M $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 8.33 8.83 Ars Pharmaceuticals Inc
Gross Profit Margin (TTM) 78.09% 85.39% Vertex Pharmaceuticals Inc.
Revenue per Share (TTM) $1 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $-1.74 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 0.93 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 41.46% 1.78% Vertex Pharmaceuticals Inc.

Ars Pharmaceuticals Inc vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

SPRY
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Ars Pharmaceuticals Inc-1.80%8.94%0.79%-2.94%-1.55%-22.54%
Vertex Pharmaceuticals Inc.0.76%-2.49%-1.11%-12.54%-1.86%-5.98%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Ars Pharmaceuticals Inc-37.14%25.28%-68.54%120.15%120.15%120.15%
Vertex Pharmaceuticals Inc.1.24%34.08%113.19%376.31%717.28%1,190.86%

Performance & Financial Health Analysis: Ars Pharmaceuticals Inc vs Vertex Pharmaceuticals Inc.

MetricSPRYVRTX
Market Information
Market Cap i$778.49M$109.45B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i1,294,5501,057,061
90 Day Avg. Volume i1,538,3271,272,097
Last Close$8.74$428.34
52 Week Range$6.66 - $18.90$362.50 - $507.92
% from 52W High-53.76%-15.67%
All-Time High$63.41 (Mar 15, 2021)$519.88 (Nov 04, 2024)
% from All-Time High-86.22%-17.61%
Growth Metrics
Quarterly Revenue Growth-0.68%0.10%
Quarterly Earnings Growth-0.68%0.31%
Financial Health
Profit Margin (TTM) i-2.03%0.33%
Operating Margin (TTM) i-1.48%0.40%
Return on Equity (TTM) i-0.92%0.23%
Debt to Equity (MRQ) i147.4910.91
Cash & Liquidity
Book Value per Share (MRQ)$1.15$73.49
Cash per Share (MRQ)$2.47$26.01
Operating Cash Flow (TTM) i$-170,866,000$3.63B
Levered Free Cash Flow (TTM) i$-94,588,376$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Ars Pharmaceuticals Inc vs Vertex Pharmaceuticals Inc.

MetricSPRY (Apr 22, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i168.2528.40
Forward P/E i-10.3519.95
PEG Ratio i-10.350.88
Price to Sales (TTM) i9.249.22
Price to Book (MRQ) i6.815.92
Market Capitalization
Market Capitalization i$778.49M$109.45B
Enterprise Value i$702.02M$105.96B
Enterprise Value Metrics
Enterprise to Revenue i8.338.83
Enterprise to EBITDA i-3.9421.78
Risk & Other Metrics
Beta i0.930.37
Book Value per Share (MRQ) i$1.15$73.49

Financial Statements Comparison: Ars Pharmaceuticals Inc vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSPRY (2025)VRTX (2025)
Revenue/Sales i84.28M12.00B
Cost of Goods Sold i20.42M1.65B
COGS % of Revenue i24.2%13.8%
Gross Profit i63.86M10.35B
Gross Margin i75.8%86.2%
Research & Development i13.18M4.04B
Operating Income (EBIT) i-179.45M4.55B
Operating Margin i-212.9%37.9%
EBITDA i-168.78M5.25B
EBITDA Margin i-200.3%43.7%
Pre-Tax Income i-171.38M4.64B
Pre-Tax Income % of Revenue i-203.3%38.7%
Income Tax i-80,000690.00M
Income Tax % of Revenue i-0.1%5.7%
Net Income (Profit) i-171.30M3.95B
Profit Margin i-203.3%32.9%

Balance Sheet & Liquidity Metrics

MetricSPRY (2025)VRTX (2025)
Cash & Equivalents i41.32M5.08B
Total Current Assets i284.90M11.20B
Total Current Assets % of Revenue i338.0%93.3%
Total Current Liabilities i39.15M3.86B
Total Current Liabilities % of Revenue i46.4%32.2%
Long-Term Debt i96.37M1.95B
Long-Term Debt % of Revenue i114.4%16.3%
Total Shareholders Equity i114.26M18.67B
Retained Earnings i-294.60M13.56B
Retained Earnings % of Revenue i-349.6%113.0%
Property, Plant & Equipment iN/A1.56B

Cash Flow Statement Comparison

MetricSPRY (2025)VRTX (2025)
Operating Cash Flow i-192.56M3.77B
Operating Cash Flow % of Revenue i-228.5%31.4%
Capital Expenditures i-339,000-437.60M
Free Cash Flow i-171.21M3.19B
FCF Margin i-203.1%26.6%
Debt Repayment iN/A-5.40M
Common Stock Repurchase iN/A-2.39B

Short Interest & Institutional Ownership Analysis

MetricSPRYVRTX
Shares Short i25.34M4.02M
Short Ratio i15.692.80
Short % of Float i41.46%1.78%
Shares Outstanding i99.29M253.99M
Float Shares i41.04M253.24M
% Held by Insiders i16.75%0.21%
% Held by Institutions i93.60%97.60%
% Held by Public i-10.35%2.19%

Dividend Analysis & Yield Comparison: Ars Pharmaceuticals Inc vs Vertex Pharmaceuticals Inc.

MetricSPRYVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A